Northern Trust
RPRX icon

Northern Trust’s Royalty Pharma RPRX Stock Holding History

Northern Trust’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265M Buy
4,718,859
+910,124
+24% +$47.4M 0.03% 426
2026
Q1 		$183M Sell
3,808,735
-194,587
-5% -$8.52M 0.02% 514
2025
Q4 		$155M Sell
4,003,322
-71,917
-2% -$2.74M 0.02% 571
2025
Q3 		$144M Buy
4,075,239
+53,389
+1% +$1.93M 0.02% 595
2025
Q2 		$145M Buy
4,021,850
+1,045,593
+35% +$34.6M 0.02% 577
2025
Q1 		$92.7M Sell
2,976,257
-354,172
-11% -$11.2M 0.01% 742
2024
Q4 		$85M Buy
3,330,429
+376,619
+13% +$9.99M 0.01% 801
2024
Q3 		$83.6M Sell
2,953,810
-343,467
-10% -$9.51M 0.01% 732
2024
Q2 		$86.9M Buy
3,297,277
+484,144
+17% +$13.4M 0.01% 696
2024
Q1 		$85.4M Buy
2,813,133
+178,958
+7% +$5.28M 0.01% 689
2023
Q4 		$74M Buy
2,634,175
+36,226
+1% +$996K 0.01% 760
2023
Q3 		$70.5M Buy
2,597,949
+224,261
+9% +$6.66M 0.01% 740
2023
Q2 		$73M Sell
2,373,688
-104,040
-4% -$3.52M 0.01% 723
2023
Q1 		$89.3M Buy
2,477,728
+48,275
+2% +$1.79M 0.02% 642
2022
Q4 		$96M Buy
2,429,453
+78,769
+3% +$3.29M 0.02% 596
2022
Q3 		$94.5M Sell
2,350,684
-32,350
-1% -$1.38M 0.02% 563
2022
Q2 		$100M Sell
2,383,034
-25,650
-1% -$1.05M 0.02% 562
2022
Q1 		$93.8M Buy
2,408,684
+147,062
+7% +$5.77M 0.02% 668
2021
Q4 		$90.1M Buy
2,261,622
+592,948
+36% +$23M 0.01% 713
2021
Q3 		$60.3M Buy
1,668,674
+450,183
+37% +$17.5M 0.01% 946
2021
Q2 		$49.9M Sell
1,218,491
-87,142
-7% -$3.71M 0.01% 1139
2021
Q1 		$57M Buy
1,305,633
+558,274
+75% +$26.5M 0.01% 1017
2020
Q4 		$37.4M Buy
747,359
+197,318
+36% +$8.37M 0.01% 1320
2020
Q3 		$23.1M Buy
550,041
+391,165
+246% +$16.8M 0.01% 1514
2020
Q2 		$7.71M Buy
+158,876
New +$7.86M ﹤0.01% 2264

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust's RPRX Position: Q2 2026 in Review

Northern Trust increased its Royalty Pharma (RPRX) stake by 24% in Q2 2026, buying an estimated $47.4M and bringing the position to 4,718,859 shares worth $265M. The position accounts for 0.03% of the portfolio, ranked #426.

Northern Trust first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Northern Trust held 4,718,859 shares of Royalty Pharma worth $265M as of Q2 2026.
  • Northern Trust bought 910,124 Royalty Pharma shares in Q2 2026, an estimated $47.4M.
  • Royalty Pharma made up 0.03% of Northern Trust's portfolio in Q2 2026, its #426 holding.
  • Northern Trust first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.